|3.||Rare Diseases (Rare Disease)
|1.||Blalock, Travis W: 1 article (01/2012)|
|2.||Davis, Loretta S: 1 article (01/2012)|
|3.||Turrentine, Jake E: 1 article (01/2012)|
|4.||Kircik, Leon: 1 article (01/2010)|
|5.||García-Vargas, Alejandro: 1 article (08/2007)|
|6.||Sandoval-Tress, Cecilia: 1 article (08/2007)|
|7.||Mayorga-Rodríguez, Jorge Arturo: 1 article (08/2007)|
|8.||Gottlieb, Alice B: 1 article (05/2003)|
|9.||Ford, Rosanne Odom: 1 article (05/2003)|
|10.||Spellman, Mary C: 1 article (05/2003)|
|1.||Adrenal Cortex Hormones (Corticosteroids)IBA
|2.||Griseofulvin (Grifulvin V)FDA LinkGeneric
|3.||Betamethasone (Celestone)FDA Link
01/01/2003 - "A new formulation of betamethasone valerate 0.1% in a thermophobic, low-residue, foam vehicle (Bettamousse) (BVM) has become available for the topical treatment of scalp dermatoses. "
01/01/2003 - "A new formulation of betamethasone valerate 0.12% in a thermophobic, low-residue foam vehicle (Bettamousse trade mark, Mipharm, Italy; BVM) is available for the treatment of scalp dermatoses. "
06/01/2000 - "A new preparation of betamethasone valerate in a novel foam vehicle is available for treatment of scalp dermatoses. "
07/01/2001 - "Although betamethasone valerate (BMV) foam, 0.12% (Luxiq, Connectics Corporation, Palo Alto, CA) is approved by the Food and Drug Administration for the treatment of corticosteroid-responsive scalp dermatoses, no data are available for its use on nonscalp psoriasis. "
|4.||Clobetasol (Clobetasol Propionate)FDA LinkGeneric
05/01/2003 - "Clobetasol propionate foam 0.05% (Connetics Corporation, Palo Alto, CA) is approved by the United States Food and Drug Administration for the treatment of corticosteroid-responsive scalp dermatoses, but there is only limited data available for its efficacy and tolerability in treating dermatoses which affect nonscalp sites. "